相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Next generation flow cytometry for MRD detection in patients with AL amyloidosis
Esftathios Kastritis et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2021)
Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis
Eli Muchtar et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2020)
Revisiting complete response in light chain amyloidosis
Surbhi Sidana et al.
LEUKEMIA (2020)
Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis
Eli Muchtar et al.
LEUKEMIA (2020)
IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features
Surbhi Sidana et al.
LEUKEMIA (2020)
Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance
Subhayan Chattopadhyay et al.
LEUKEMIA (2020)
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis
Surbhi Sidana et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis
Surbhi Sidana et al.
BLOOD CANCER JOURNAL (2020)
Systemic amyloidosis: moving into the spotlight
Oliver C. Cohen et al.
LEUKEMIA (2020)
Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis
Shayna Sarosiek et al.
BLOOD CANCER JOURNAL (2020)
Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis
Andrew Staron et al.
BLOOD ADVANCES (2020)
Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis
Jithma P. Abeykoon et al.
LEUKEMIA (2019)
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
Thierry Facon et al.
BLOOD (2019)
A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib
Richa Manwani et al.
BLOOD (2019)
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis
Efstathios Kastritis et al.
BLOOD CANCER JOURNAL (2018)
What does minimal residual disease mean in AL amyloidosis?
Paolo Milani et al.
EXPERT OPINION ON ORPHAN DRUGS (2018)
Systemic immunoglobulin light chain amyloidosis
Giampaolo Merlini et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies
Giovanni Palladini et al.
BLOOD (2018)
The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment
Eli Muchtar et al.
BLOOD (2017)
Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy
Jean-Luc Harousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
J. Flores-Montero et al.
LEUKEMIA (2017)
Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage
Luisa Diomede et al.
ANTIOXIDANTS & REDOX SIGNALING (2017)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis
Katharina Lisenko et al.
CANCER MEDICINE (2016)
New criteria for response assessment: role of minimal residual disease in multiple myeloma
Bruno Paiva et al.
BLOOD (2015)
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis
Luisa Diomede et al.
BLOOD (2014)
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2014)
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis
Bruno Paiva et al.
BLOOD (2011)
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL
Giovanni Palladini et al.
BLOOD (2006)
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
分享论文
